BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

12373 related articles for article (PubMed ID: 11092043)

  • 1. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
    Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
    Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
    Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
    Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIA, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
    Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
    Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
    Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
    Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
    J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
    Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
    Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma.
    Vucetić B; Rogan SA; Hrabac P; Hudorović N; Cupić H; Lukinac L; Ledinsky M; Matejcić A; Lovricević I; Zekan M
    Melanoma Res; 2008 Jun; 18(3):201-7. PubMed ID: 18477894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
    Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
    Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.
    Reiniger IW; Schaller UC; Haritoglou C; Hein R; Bosserhoff AK; Kampik A; Mueller AJ
    Graefes Arch Clin Exp Ophthalmol; 2005 Nov; 243(11):1161-6. PubMed ID: 15906071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
    Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
    J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Melanoma inhibitory activity (MIA). Evaluation of a new tumor-associated antigen as a serum marker for uveal melanomas].
    Schaller UC; Mueller AJ; Bosserhoff AK; Haraida S; Löhrs U; Buettner R; Kampik A
    Ophthalmologe; 2000 Jun; 97(6):429-32. PubMed ID: 10916387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
    Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
    Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
    Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
    Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population.
    Li C; Liu J; Jiang L; Xu J; Ren A; Lin Y; Yao G
    Medicine (Baltimore); 2021 Feb; 100(8):e24840. PubMed ID: 33663104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 619.